低剂量与常规剂量秋水仙碱预防降尿酸治疗初期痛风发作的疗效比较
该回顾性队列研究纳入419例起始别嘌醇或非布司他联合秋水仙碱治疗的痛风患者,比较常规剂量(1.2 mg/日)与低剂量(0.6 mg/日)秋水仙碱预防痛风发作的效果。经IPTW调整后,两组痛风发作率无显著差异,但低剂量组不良事件发生率显著低于常规剂量组。
要点
- 低剂量与常规剂量秋水仙碱预防痛风发作的疗效无显著差异。
- 低剂量秋水仙碱的不良事件发生率显著低于常规剂量。
- 降尿酸治疗初期可考虑使用低剂量秋水仙碱预防发作。
核心结论
- 低剂量秋水仙碱(0.6 mg/日)能充分预防降尿酸治疗初期的痛风发作,且不良事件更少。
研究设计与样本
- 回顾性队列研究,纳入419例起始别嘌醇或非布司他联合秋水仙碱治疗的痛风患者,随访3个月。
- 采用逆概率治疗加权(IPTW)和加权逻辑回归分析评估治疗效果,并按意向治疗(ITT)和符合方案(PP)分析。
主要发现
- 419例患者中,177例(42.2%)接受低剂量秋水仙碱,242例(57.8%)接受常规剂量秋水仙碱。
- 低剂量组BMI和估算肾小球滤过率较低,心血管疾病发生率较高。
- IPTW调整后,痛风发作率在低剂量与常规剂量组间无显著差异(ITT:14.3% vs 11.3%;OR 1.309,95%CI 0.668-2.566,P=0.432;PP:15.3% vs 10.0%;OR 1.623,95%CI 0.765-3.443,P=0.207)。
- 低剂量组不良事件率显著低于常规剂量组(ITT:8.2% vs 17.9%;OR 0.410,95%CI 0.217-0.777,P<0.05;PP:8.4% vs 17.2%;OR 0.442,95%CI 0.223-0.878,P<0.05)。
临床怎么用
- 在起始降尿酸治疗的痛风患者中,可优先考虑低剂量秋水仙碱(0.6 mg/日)预防发作,以降低不良事件风险。
局限性
- 本研究为回顾性队列研究,可能存在残余混杂。
- 低剂量组与常规剂量组在BMI、eGFR和心血管疾病发生率上存在基线差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study was to compare the prophylactic effect of regular-dose (RD, 1.2 mg/day) vs low-dose (LD, 0.6 mg/day) colchicine on gout flare when initiating urate-lowering therapy. METHODS: In this retrospective cohort study, we included gout patients who were initiated on either allopurinol or febuxostat, in combination with colchicine therapy and followed them up for 3 months. We analysed the rates of gout flare and adverse events according to the dose of colchicine. We performed the inverse probability of treatment weighting (IPTW) and weighted logistic regression analysis to assess the treatment effect. Analysis of gout flares and adverse events was performed on an intention-to-treat (ITT) and per-protocol (PP) basis. RESULTS: Of the total of 419 patients with gout, 177 patients (42.2%) received LD colchicine, whereas 242 patients (57.8%) received RD colchicine. Lower BMI and estimated glomerular filtration rate, and higher incidence of cardiovascular disease were seen in the LD group than in the RD group. In IPTW-adjusted analysis, events of gout flare were not significantly different between the LD and RD groups [ITT: 14.3% vs 11.3%; odds ratio (OR): 1.309, 95% CI: 0.668, 2.566, P = 0.432; PP: 15.3% vs 10.0%; OR: 1.623, 95% CI: 0.765, 3.443, P = 0.207]. However, LD colchicine was associated with a lower rate of adverse events than RD colchicine [ITT: 8.2% vs 17.9%; OR: 0.410, 95% CI: 0.217, 0.777; P < 0.05; PP: 8.4% vs 17.2%; OR: 0.442, 95% CI: 0.223, 0.878; P < 0.05]. CONCLUSION: Our data suggest that LD colchicine can adequately prevent gout flare with fewer adverse events compared with RD colchicine.
引用
- Ahn SM, Oh JS, Hong S, et al. Comparative efficacy of low-dose versus regular-dose colchicine to prevent flares in gout patients initiated on urate-lowering therapies. Rheumatology (Oxford). 2021. PMID: 33764413. doi:10.1093/rheumatology/keab303
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。